The serum concentration of Paricalcitol can be increased when it is combined with Indinavir. The metabolism of Paricalcitol can be decreased when combined with Crizotinib. The serum concentration of Paricalcitol can be increased when it is combined with Voriconazole. The metabolism of Paricalcitol can be decreased when combined with Rucaparib. The risk or severity of adverse effects can be increased when Calcium lactate is combined with Paricalcitol. The risk or severity of adverse effects can be increased when Calcium Citrate is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Olaparib. The serum concentration of Paricalcitol can be increased when it is combined with Palbociclib. The metabolism of Paricalcitol can be increased when combined with Rifampicin. The serum concentration of Paricalcitol can be increased when it is combined with Lopinavir. The serum concentration of Paricalcitol can be increased when it is combined with Stiripentol. Paricalcitol may increase the arrhythmogenic activities of Ouabain. Cyclopenthiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Verapamil. The serum concentration of Conivaptan can be increased when it is combined with Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Ziprasidone. The metabolism of Paricalcitol can be decreased when combined with Dihydroergotamine. Metolazone may increase the hypercalcemic activities of Paricalcitol. Chlorthalidone may increase the hypercalcemic activities of Paricalcitol. Methyclothiazide may increase the hypercalcemic activities of Paricalcitol. Hydrochlorothiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Delavirdine. The risk or severity of adverse effects can be increased when Casein is combined with Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Ivacaftor. The metabolism of Paricalcitol can be decreased when combined with Lovastatin. Quinethazone may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Paricalcitol can be increased when it is combined with Mifepristone. The serum concentration of Paricalcitol can be decreased when it is combined with Dabrafenib. The serum concentration of Paricalcitol can be increased when it is combined with Simeprevir. The serum concentration of Paricalcitol can be decreased when it is combined with Mitotane. The metabolism of Paricalcitol can be decreased when combined with Sulfisoxazole. The metabolism of Paricalcitol can be decreased when combined with Venlafaxine. Polythiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Diltiazem. The metabolism of Paricalcitol can be increased when combined with Nevirapine. The metabolism of Paricalcitol can be decreased when combined with Nilotinib. The metabolism of Paricalcitol can be decreased when combined with Fosamprenavir. Hydroflumethiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Fluvoxamine. The serum concentration of Paricalcitol can be increased when it is combined with Boceprevir. The metabolism of Paricalcitol can be decreased when combined with Doxycycline. The metabolism of Paricalcitol can be decreased when combined with Ticlopidine. The serum concentration of Paricalcitol can be increased when it is combined with Ceritinib. The metabolism of Paricalcitol can be decreased when combined with Erythromycin. The metabolism of Paricalcitol can be decreased when combined with Fluconazole. The serum concentration of Paricalcitol can be increased when it is combined with Posaconazole. The metabolism of Paricalcitol can be increased when combined with Phenytoin. The metabolism of Paricalcitol can be increased when combined with Lumacaftor. The serum concentration of Paricalcitol can be decreased when it is combined with St. John's Wort. Indapamide may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcidiol. The metabolism of Paricalcitol can be decreased when combined with Imatinib. The metabolism of Paricalcitol can be increased when combined with Phenobarbital. Danazol may increase the hypercalcemic activities of Paricalcitol. The serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol. The metabolism of Paricalcitol can be increased when combined with Carbamazepine. The metabolism of Paricalcitol can be decreased when combined with Cyclosporine. The serum concentration of Paricalcitol can be increased when it is combined with Cobicistat. Trichlormethiazide may increase the hypercalcemic activities of Paricalcitol. Paricalcitol may increase the arrhythmogenic activities of Digitoxin. The serum concentration of Paricalcitol can be increased when it is combined with Clarithromycin. The metabolism of Paricalcitol can be decreased when combined with Clemastine. The metabolism of Paricalcitol can be decreased when combined with Bortezomib. The serum concentration of Paricalcitol can be increased when it is combined with Netupitant. The serum concentration of Paricalcitol can be increased when it is combined with Osimertinib. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcipotriol. The serum concentration of Paricalcitol can be increased when it is combined with Itraconazole. The serum concentration of Paricalcitol can be increased when it is combined with Ketoconazole. The metabolism of Paricalcitol can be decreased when combined with Clotrimazole. The serum concentration of Sucralfate can be increased when it is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Colesevelam. Paricalcitol may increase the arrhythmogenic activities of Oleandrin. The metabolism of Paricalcitol can be increased when combined with Rifapentine. The risk or severity of adverse effects can be increased when Calcium glubionate is combined with Paricalcitol. The risk or severity of adverse effects can be increased when Doxercalciferol is combined with Paricalcitol. Paricalcitol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine). The serum concentration of Paricalcitol can be decreased when it is combined with Vemurafenib. The serum concentration of Paricalcitol can be increased when it is combined with Telithromycin. Bendroflumethiazide may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Calcium Acetate is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Deferasirox. The serum concentration of Paricalcitol can be increased when it is combined with Atazanavir. The serum concentration of Paricalcitol can be increased when it is combined with Fosaprepitant. The serum concentration of Paricalcitol can be increased when it is combined with Saquinavir. The serum concentration of Paricalcitol can be decreased when it is combined with Tocilizumab. The serum concentration of Paricalcitol can be increased when it is combined with Nelfinavir. The serum concentration of Paricalcitol can be increased when it is combined with Dasatinib. The metabolism of Paricalcitol can be decreased when combined with Isradipine. The serum concentration of Paricalcitol can be increased when it is combined with Fusidic Acid. The risk or severity of adverse effects can be increased when Calcium Chloride is combined with Paricalcitol. Paricalcitol may increase the arrhythmogenic activities of Proscillaridin. The serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine. The serum concentration of Paricalcitol can be increased when it is combined with Amiodarone. The metabolism of Paricalcitol can be decreased when combined with Sildenafil. The serum concentration of Paricalcitol can be decreased when it is combined with Colestipol. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Ergocalciferol. The serum concentration of Paricalcitol can be increased when it is combined with Idelalisib. The serum concentration of Paricalcitol can be decreased when it is combined with Mineral oil. The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Enzalutamide. The metabolism of Paricalcitol can be decreased when combined with Ranolazine. The metabolism of Paricalcitol can be decreased when combined with Isavuconazonium. The serum concentration of Paricalcitol can be decreased when it is combined with Siltuximab. The metabolism of Paricalcitol can be increased when combined with Fosphenytoin. The metabolism of Paricalcitol can be decreased when combined with Dronedarone. The metabolism of Paricalcitol can be increased when combined with Primidone. The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Sarilumab. The serum concentration of Paricalcitol can be increased when it is combined with Darunavir. The metabolism of Paricalcitol can be increased when combined with Rifabutin. The serum concentration of Paricalcitol can be increased when it is combined with Telaprevir. The serum concentration of Paricalcitol can be increased when it is combined with Luliconazole. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin. The serum concentration of Paricalcitol can be increased when it is combined with Nefazodone. The serum concentration of Paricalcitol can be increased when it is combined with Aprepitant. Paricalcitol may increase the arrhythmogenic activities of Deslanoside. The metabolism of Paricalcitol can be increased when combined with Pentobarbital. The risk or severity of adverse effects can be increased when Calcium Gluceptate is combined with Paricalcitol. The risk or severity of adverse effects can be increased when Paricalcitol is combined with Dihydrotachysterol. Paricalcitol may increase the arrhythmogenic activities of Acetyldigitoxin. The risk or severity of adverse effects can be increased when Calcium gluconate is combined with Paricalcitol. The serum concentration of Paricalcitol can be decreased when it is combined with Bosentan. The serum concentration of Paricalcitol can be decreased when it is combined with Orlistat. Chlorothiazide may increase the hypercalcemic activities of Paricalcitol. The metabolism of Paricalcitol can be decreased when combined with Atomoxetine.